MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-13-2026
Vertex Pharmaceuticals Incorporated Operating Cash Flow 2011-2026 | VRTX
Annual Operating Cash Flow Vertex Pharmaceuticals Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.63 B | -493 M | 3.54 B | 4.13 B | 2.64 B | 3.25 B | 1.57 B | 1.27 B | 845 M | 236 M | -365 M | -573 M | -60.7 M | 268 M | 144 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.13 B | -573 M | 1.34 B |
Quarterly Operating Cash Flow Vertex Pharmaceuticals Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 819 M | - | - | - | 1.31 B | - | - | - | 900 M | - | 3.05 B | - | 956 M | - | 1.65 B | - | 921 M | - | 2.76 B | 1.85 B | 816 M | - | 1.12 B | 789 M | 325 M | - | 956 M | 574 M | 253 M | - | 617 M | 447 M | 266 M | - | 91.4 M | 25.7 M | -15.1 M | - | -395 M | -333 M | -222 M | - | -391 M | -304 M | -176 M | - | -80.4 M | -66.7 M | -65.8 M | - | 227 M | 121 M | 2.92 M | - | - | - | -187 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.05 B | -395 M | 532 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Benitec Biopharma
BNTC
|
-23.6 M | $ 10.98 | -4.52 % | $ 452 M |  USA |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 221.88 | -0.87 % | $ 5 B |  Danmark |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Milestone Pharmaceuticals
MIST
|
-49 M | $ 1.36 | -20.0 % | $ 45.5 M |  Canada |
 |
Pharming Group N.V.
PHAR
|
74 M | $ 15.36 | -0.71 % | $ 7.59 B |  Niderland |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Inventiva S.A.
IVA
|
-47.6 M | $ 5.78 | -4.3 % | $ 138 M | France |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Tiziana Life Sciences PLC
TLSA
|
-21.8 M | $ 1.21 | -3.97 % | $ 71.5 M |  Britain |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
PainReform Ltd.
PRFX
|
-12.6 M | $ 2.28 | -0.44 % | $ 1.03 M |  Israel |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-22.3 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
Assembly Biosciences
ASMB
|
-41.1 M | $ 28.46 | 3.45 % | $ 319 M | USA |
 |
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-206 M | $ 1.37 | -4.2 % | $ 350 M | Britain |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Axsome Therapeutics
AXSM
|
-93.4 M | $ 156.92 | -1.23 % | $ 7.81 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 3.4 | -3.68 % | $ 1.02 B | Canada |
 |
Atreca
BCEL
|
-80.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioMarin Pharmaceutical
BMRN
|
828 M | $ 54.13 | -1.64 % | $ 10.4 B | USA |
 |
Calithera Biosciences
CALA
|
-66.3 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
-92.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-75.6 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-17.8 M | - | -74.18 % | $ 955 K | USA |
 |
Compugen Ltd.
CGEN
|
31.6 M | $ 2.09 | -0.95 % | $ 195 M | Israel |
 |
Coherus BioSciences
CHRS
|
-139 M | $ 1.52 | -5.59 % | $ 178 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-31.1 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-196 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Burford Capital Limited
BUR
|
181 M | $ 7.7 | -5.87 % | $ 1.29 B | Britain |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-64.5 M | $ 8.6 | -3.8 % | $ 115 M | USA |
 |
Curis
CRIS
|
-39.6 M | $ 0.77 | 1.89 % | $ 4.86 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |